21/05/2026 11.10-12.10 Aging with HIV: survival is not enough

Sala Antares

OC 1 **Comprehensive Aging Profile in Elderly People Living with HIV**

M.R. Petrara[1], S. Pavanello[2], L. Sasset[3], E. Ruffoni[1], L. Cannella[2], F. Carmona[1], M. Morello[1], L. Calandrino[3], S. Cancian[3], E. Masetto[4], M. Campisi[2], S. De Vidi[2], A. De Rossi[5], S. Giunco[5], A.M. Cattelan[3]
[1]Immunology and Diagnostic Molecular Oncology Unit, Veneto Institute of Oncology IOV – IRCCS, Padova, Italy, [2]Department of Cardiac, Thoracic, and Vascular Sciences and Public Health, University of Padova, Padua, Italy; Occupational Medicine Unit, University Hospital of Padua, Padova, Italy, [3]Infectious and Tropical Diseases Unit, Padova University Hospital, Padova, Italy, [4]Clinical Trials and Biostatistics Unit, Veneto Institute of Oncology IOV–IRCCS, Padova, Italy, [5]Oncology and Immunology Section, Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy

OC 2 **Mapping of Psychosocial and Relational Determinants of Healthy Aging in People Living with HIV: The Italian Healthy Aging Survey**

A. Castro[2], G. Giupponi[3], P. Meli[4], M. Farinella[5], F. Von Schloesser[6], S. Patrucco[7], D. Masci[8], M. Stagnitta[9], M. Cernuschi[10], L. Butini[11], A. Moznich[12], S. Cecere[13], H. Gebdo[14], G. Guaraldi[1]
[1]University di Modena e Reggio Emilia, Modena, Italy, [2]University di Milano Bicocca, Milan, Italy, [3]LILA Naz Como Italy, [4]CICA, Milano, Italy, [5]Circolo di Cultura Omosessuale Mario Mieli Roma, Italy, [6]NADIR Roma Italy, [7]Arcobaleno Aids Torino Italy, [8]Fondazione Villa Maraini Roma Italy, [9]CNCA Roma Italy, [10]ASA Milano Italy, [11]Anlaids Roma Italy, [12]NPS Italia Milan Italy, [13]Plus-rete Persone LGBT+ Sieropositive Bologna Italy, [14]CDCP Trieste Italy

OC 3 **Polypharmacy and gender-specific vulnerability to cognitive and physical function among older people living with HIV: data from GEPPO cohort**

B. Fioretti[1], S. Calza[2], A. Salvini[3], S. Arsuffi[1], C. Candela[4], B.M. Celesia[5], P. Bonfanti[6], M. Ferrara[7], A. Cattelan[8], G. Madeddu[9], G. De Socio[10], G. Orofino[11], A. Calcagno[12], G. Guaraldi[13], A. Marengoni[3], E. Focà[1]
[1]Division of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, University of Brescia and ASST Spedali Civili of Brescia, Brescia, Italy, [2]Unit of Biostatistics and Bioinformatics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy, [3]Division of Geriatric Medicine, Department of Clinical and Experimental Sciences, University of Brescia and ASST Spedali Civili of Brescia, Brescia, Italy, [4]Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy, [5]ARNAS 'Garibaldi' UOC Malattie Infettive Catania, Catania, Italy, [6]Clinic of Infectious Diseases, IRCCS San Gerardo dei Tintori, ALA Milano Onlus and School of Medicine, University of Milan-Bicocca, Monza, Italy, [7]Unit of Infectious Diseases, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Torino, Italy, [8]Infectious and Tropical Diseases Unit, Padua University Hospital, Padova, Italy, [9]Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Science, University of Sassari, Sassari, Italy, [10]Department of Medicine, Clinic of Infectious Diseases, University of Perugia, Perugia, Italy, [11]Unit of Infectious Diseases, «Division A», Ospedale Amedeo di Savoia, Turin, Italy, [12]Division of Infectious Diseases, Department of Translational medicine, UPO - Università del Piemonte Orientale, Novara, Italy, [13]Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy

OC 4 **Semaglutide in people with HIV: a metabolic health intervention toward the fourth 90%**

M. Menozzi[1], J. Milic[2], G. Cuomo[1], A. Cervo[1], G. Mancini[1], C. Mussini[2], G. Guaraldi[2]
[1]Infectious Disease Clinic, Azienda Ospedaliero-Universitaria Policlinico di Modena - Modena HIV Metabolic Clinic, Modena, Italy, [2]Infectious Disease Clinic, University of Modena and Reggio Emilia, Modena HIV Metabolic Clinic, Modena Italy

21/05/2026 14.00-15.00 Reaching the unreached: community strategies for HIV testing and care

Sala Cassiopea 2

OC 5 **Leveraging harmonised and disaggregated data for stronger community-based testing responses: Insights from the COBATEST network**

L. Fernàndez-López[1,2,3], M. Gogishvili[1, 2], M. Alarcón[1,2], P. Piselli[4], J. Aceitón[1,2], C. Folch[1,2,3], and COBATEST Network
[1]Centre of Epidemiological Studies of HIV/AIDS and STI of Catalonia (CEEISCAT), Health Department, Generalitat de Catalunya, Badalona, Spain, [2]Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain, [3]CIBER Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain, [4]INMI L. Spallanzani IRCCS, Clinical Epidemiology & Biostatistics Unit - Department of Epidemiology and Preclinical Research, Rome, Italy

OC 6 **The value of promoting hepatitis and HIV screening in high-prevalence populations: the "Test in the City" project**

*P. Meli[1], I. Mercurio[1], V. Gotti[1], C. Pellegris[1], F. Gritti[1], E. Zanetti[1], F. Maggiolo[1], R. Carissoli[2], L. Comi[3], S. Venturelli[3] on behalf of 'Test in the City' Working Group composed by 14 Italian Fast-Track Cities**
[1]Cooperativa Don Giuseppe Monticelli/Bergamo Fast-track City Network, Bergamo, Italy, [2]Arcigay Bergamo Cives/Bergamo Fast-track City Network, Bergamo, Italy, [3]ASST Papa Giovanni XXIII, Bergamo, Italy
*Ancona, Bari, Bergamo, Cremona, Brescia, Firenze, Genova, Milano, Latina, Legnano, Padova, Palermo, Sanremo, Torino

OC 7 **From regulation to implementation: a cross-country ecological analysis of HIV testing frameworks and late diagnosis in Europe**

L. Bortolani, A. Lazzaro, F. Alessi, M. Ridolfi, E. Altavilla, V. Bleve, G. Ceccarelli, C.M. Mastroianni, G. d'Ettorre
Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy

OC 8 Characteristics of individuals tested for HIV within Community-Based Voluntary Counselling and Testing (CBVCT) activities in Italy (2019-2025)

P. Piselli[1], E. Gennaro[1], C. Cimaglia[1], G. Giupponi[2], L. Fernàndez-López[3], L. Cosmaro[4], M. Cernuschi[5], P. Meli[6], S. Mattioli[7], N. Frattini[8], M. Farinella[9], L. Rancilio[10], I. Pennini[11], S. Patrucco[12], A. Camposeragna[13], D. Masci[14], G. Moi[15], C. Nicoara[16], L. del Negro[17], M. Gogishvilli[3], A. Caioli[1], S. Leone[1], A. Navarra[1], A. Caraglia[18], E. Girardi[1], for the Working Group of the project "Contribution of the Association to the continuum of care of persons living with HIV and AIDS"

[1]INMI L. Spallanzani, Rome, Italy, [2]LILA Como, Como, Italy, [3]Centre of Epidemiological Studies of HIV/AIDS and STI of Catalonia (CEEISCAT), Health Department, Generalitat de Catalunya, BADALONA, Spain, [4]LILA Milano, Milan, Italy, [5]Milano Checkpoint, Milan, Italy, [6]CICA, Bergamo, Italy, [7]PLUS, Bologna, Italy, [8]Associazione Solidarietà AIDS (ASA), Milan, Italy, [9]Circolo di Cultura Omosessuale "Mario Mieli", Rome, Italy, [10]CARITAS Ambrosiana, Milan, Italy, [11]Arcigay, Padua, Italy, [12]Arcobaleno AIDS, Turin, Italy, [13]CNCA, Rome, Italy, [14]Fondazione Villa Maraini, Rome, Italy, [15]Movimento Omosessuale Sardo (MOS), Sassari, Italy, [16]Network Persone Sieropostive (NPS) Italia, Milan, Italy, [17]Checkpoint PLUS Roma, Rome, Italy, [18]Ministero della Salute, Rome, Italy

21/05/2026 15.05-16.05 Evolving liver care in people with and without HIV: prevention, innovation, and long term

Sala Pegaso 3

OC 9 High diagnostic yield of repeated HCV screening in addiction services: compared findings from two large-scale campaigns in 2023 and 2025

A. Bilotta[1], E. Princic[1], S. Babudieri[1], G. Madeddu[1], G. Seu[2], P. Milia[2], I. Maida[1]

[1]Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, [2]Azienda Sanitaria Locale (ASL) di Sassari, Sassari, Italy

OC 10 Vitamin D Status and Hepatic Steatosis in People with HIV: Evidence from Paired Measurements

J. Milic[1,2], L. Salmoni[3], S. Kaleci[2], L. Gozzi[4], F. Cinque[5], T. Albano[4], M. Ricciardetto[4], I. Avanzini[4], E. Delmonte[4], M. Menozzi[4], G. Cuomo[4], G. Mancini[4], R. Lombardi[5], C. Mussini[1,2,4], G. Sebastiani[6], G. Guaraldi[1,2,4]

[1]Modena HIV Metabolic Clinic, University of Modena and Reggio Emilia, Modena, Italy, [2]Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy, [3]Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania Luigi Vanvitelli, Naples, Italy, [4]Clinic for Infectious Diseases, University Hospital of Modena, Modena, Italy, [5]Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, [6]Division of Gastroenterology and Hepatology, and Chronic Viral Illness Service, McGill University Health Centre, Montreal, Canada

OC 11 Chronic HDV infection is characterized by distinct profiles of HBsAg isoforms underlying different disease stages

I. Grossi[1], C. Tramontozzi[1], A. Magnapera[1], S. D'Anna[1], E. Dileo[2], A. Olivero[2], L. Piermatteo[1], G. Mengozzi[2], A. Ciancio[2], A. Loglio[3], M. Viganò[3], S. Fagiuoli[3,4], P. Colombatto[5], B. Coco[5], M.R. Brunetto[5], D. Angrisani[6], A. Galeota Lanza[6], C. Magni[7], G. Rizzardini[7], V. Messina[8], M. Milella[9], A. Saracino[9], L. Marinaro[10], G. Cariti[10], V. Cossiga[11], F. Morisco[11], S. Cretella[12], G. Verucchi[13], E. Biliotti[14], G. D'Offizi[14], M. Feasi[15], E. Pontali[15], C. Coppola[16], R. Rapetti[17], M. Pirisi[17], A. Izzi[18], T. Santantonio[19], V. Di Marco[20], A. Marrone[21], N. Coppola[22], M. Rizzi[23], A.M. Cattelan[24], G.A. Niro[25], P. Toniutto[26], F.R. Ponziani[27], L.S. Belli[28], A. Federico[29], G. Bertino[30], M. Barone[31], M. Puoti[32], A. Civolan[i33], M. Distefano[34], L.A. Surace[35], R. Cozzolongo[36], E.M. Cela[37], E. Teti[38], P. Lampertico[39,40], T. Stroffolini[41], R. Salpini[1], V. Svicher[1], M. Rizzetto[2], G.P. Caviglia[2]

[1]Department of Biology, University of Rome Tor Vergata, Rome, Italy, [2]Department of Medical Sciences, University of Torino, Turin, Italy, [3]Division of Gastroenterology, Hepatology and Transplantation, ASST Papa Giovanni XXIII, Bergamo, Italy, [4]Gastroenterology, Department of Medicine, University of Milan Bicocca, Milan, Italy, [5]Department of Clinical and Experimental Medicine, Hepatology and Liver Physiopathology Laboratory and Internal Medicine Unit, University of Pisa, Pisa, Italy, [6]Hepatology Unit, AORN A. Cardarelli, Naples, Italy, [7]Division of Infectious Diseases, ASST-FBF-Sacco, Milan, Italy, [8]Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy, [9]Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, [10]Clinica Malattie Infettive UniTo, "Ospedale Amedeo di Savoia", Turin, Italy, [11]Department of Clinical Medicine and Surgery, Liver and Biliary Diseases Unit, University of Naples "Federico II", Naples, Italy, [12]Infectious Diseases Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, [13]Infectious Diseases Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy, [14]Infectious Diseases and Hepatology Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, [15]Department of Infectious Diseases, Galliera Hospital, Genoa, Italy, [16]Unit of Hepatology and Interventional Ultrasonography, Department of Internal Medicine, OORR Area Stabiese, Gragnano, Italy, [17]Internal Medicine, Azienda Ospedaliero-Universitaria "Maggiore Della Carità", Department of Translational Medicine (DiMeT), Università del Piemonte Orientale, Novara, Italy, [18]UOC di malattie infettive emergenti e ad alta contagiosità, Ospedale Cotugno, Naples, Italy, [19]Department of Medical and Surgical Sciences, Infectious Diseases Unit, University of Foggia, Foggia, Italy, [20]Section of Gastroenterology and Hepatology, Dipartimento Di Promozione Della Salute, Materno Infantile, Medicina Interna e Specialistica di Eccellenza (PROMISE), University of Palermo, Palermo, Italy, [21]Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy, [22]Infectious Diseases Unit, Department of Mental Health and Public Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy, [23]SC Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy, [24]Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, [25]Gastroenterology Unit, Fondazione Casa Sollievo Della Sofferenza IRCCS, San Giovanni Rotondo, Italy, [26]Hepatology and Liver Transplant Unit, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy, [27]Liver Unit, Centro Malattie dell'Apparato Digerente (CEMAD), Medicina Interna e Gastroenterologia, Fondazione Policlinico Universitario Gemelli IRCCS, Rome, Italy, [28]Hepatology and Gastroenterology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, [29]Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy, [30]Hepatology Unit, University Hospital Policlinico "G. Rodolico - San Marco", Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy, [31]Gastroenterology Unit, Department of Precision and Regenerative Medicine–Jonian Area–(DiMePRe-J), University of Bari "Aldo Moro", Policlinic University Hospital, Bari, Italy, [32]Division of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda; Department of Medicine, University of Milan Bicocca, Milan, Italy, [33]Teaching Hospital "Duilio Casula", Azienda Ospedaliero-Universitaria di Cagliari, Cagliari, Italy, [34]UOSD Hepatology, Ospedale Umberto I°, ASP 8 Siracusa, Siracusa, Italy, [35]Dipartimento Di Prevenzione, Azienda Sanitaria Provinciale di Catanzaro, Centro di Medicina del Viaggiatore e delle Migrazioni, P. O. Giovanni Paolo II, Lamezia Terme, Italy, [36]Gastroenterology Unit, IRCCS "S. De Bellis", Castellana Grotte, Italy, [37]Gastroenterology Unit, Riuniti Polyclinic of Foggia, Foggia, Italy, [38]Infectious Disease Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy, [39]Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, [40]CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, [41]Department of Tropical and Infectious Diseases, Policlinico Umberto I, Rome, Italy

OC 12 **Long-term outcomes in liver transplant recipients: comparison between patients living with and without HIV infection**

A. Cervo[1], M. Albertini[1,2], F. Casari[1,2], J. Milic[1,2], B. Catellani[3], P. Magistri[2,3], E. Franceschini[1,2], G.P. Guerrini[3], C. Mussini[1,2], F. Di Benedetto[2,3], G. Guaraldi[1,2]

[1]Clinic of Infectious Diseases, University Hospital of Modena, Modena, Italy, [2]Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Italy, [3]Hepato-Pancreato-Biliary Surgery and Liver Transplantation Unit, University Hospital of Modena, Modena, Italy

21/05/2026 16.10-17.35 Virological insights shaping antiviral treatment — Sala Antares

OC 13 **Eligibility for regimens containing Islatravir in the ARCA cohort in virologically suppressed people living with HIV**

M. Menozzi[1], M. Sambo[2], M.M. Santoro[3], A. Bezenchek[4,5], O. El Khalili[3], I. Giovannelli[6], G. Massobrio[7], W. Gennari[8], A. Giacomelli[9], C. Mussini[10], V. Micheli[11], V. Ricucci[12], B. Rossetti[13], F. Ceccherini-Silberstein[3], A. De Vito[14], D. Armenia[15]

[1]Clinic of Infectious Diseases, Azienda-Ospedaliero Universitaria Policlinico di Modena, Modena, Italy, [2]Infectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria Senese, Siena, Italy, [3]Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy, [4]IPRO-InformaPRO S.r.l., Rome, Italy, [5]EuResist Network GEIE, Rome, Italy, [6]Clinical Immunology, Allergy and Advanced Biotechnologies Unit, AUSL - IRCCS Reggio Emilia, Reggio Emilia, Italy, [7]Infection disease Unit, IRCCS - Policlinico San Martino Hospital, Genoa, Italy, [8]Microbiology and Virology Division, University Hospital of Modena – University of Modena and Reggio Emilia, Modena, Italy, [9]Department of Biomedicale and Clinical Sciences, Università degli studi di Milano - Department of infectious diseases, asst Fatebenefratelli Sacco, Milan, Italy, [10]Clinic of Infectious Diseases, University Hospital of Modena – University of Modena and Reggio Emilia, Modena, Italy, [11]Clinical Microbiology, Virology and Bioemergency Diagnostics, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy, [12]Hygiene Unit, IRCCS - Policlinico San Martino Hospital, Genoa, Italy, [13]Infectious Diseases Unit, USL Sud-Est Toscana, Ospedale Misericordia, Grosseto, Italy, [14]Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, [15]UniCamillus, Saint Camillus International University of Health Sciences, Rome, Italy

OC 14 **Timing of First Viral Blips Across Modern Antiretroviral Regimens: A Retrospective Analysis**

C. Gioè[1], M. Trizzino[1], L. Pipitò[1,2], C. Mascarella[2,3], D. Graceffa[2,3], C. Bonura[2,3], G. Giammanco[2,3], A. Cascio[1,2]

[1]Infectious and Tropical Diseases Unit, Sicilian Regional Reference Center for the Fight Against AIDS, AOU Policlinico "P. Giaccone", Palermo, Italy, [2]Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G D'Alessandro", University of Palermo, Palermo, Italy, [3]Microbiology and Virology Unit, AOU Policlinico "P. Giaccone", Palermo, Italy

OC 15 **Multidisciplinary assessment of the HIV-1 reservoir after switching from triple to dual antiretroviral therapy in virologically suppressed individuals, a prospective observational pilot study**

L. Fiaschi[1], N. Bartolini[1], M. Compagno[2], L. Benedetti[2], O. El Khalili[2], C. Biba[1], C. Paletti[1], I. Varasi[1], M. Iannetta[2], V. Malagnino[2], M. Santoro[2], R. Salpini[2], V. Svicher[2], F. Ceccherini-Silberstein[2], L. Sarmati[2], F. Saladini[1], M. Zazzi[1], I. Vicenti[1,3]

[1]University of Siena, Siena, Italy, [2]University of Rome Tor Vergata, Rome, Italy, [3]Saint Camillus International University of Health Sciences, Rome, Italy

OC 16 **Characterisation of HIV-1 reservoir in subjects on long-acting therapy**

A. Bergna[1], C. della Ventura[2], I. Serravalli[2], M. Liturri[2], C. Mauro[2], E. Marinosci[2], M.V. Cossu[1], C. Gervasoni[1], S. Antinori[1,2], A. Riva[1,2], G. Zehender[2], A. Lai[2]

[1]Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy, [2]Department of Biomedical and Clinical Sciences, University of Milan,Milan, Italy

OC 17 **Human and HCMV-encoded microRNAs in cerebrospinal fluid (CSF) of ART-treated People with HIV (PWH): correlation with HIV-1 replication and inflammatory markers**

G. Rozera, E. Lazzari, E. Cimini, F. Cristofanelli, E. Tartaglia, F. Smoquina, F. Forbici, G. Berno, L. Fabeni, C. Pinnetti, V. Mazzotta, A. Antinori, F. Maggi, I. Abbate

National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy

OC 18 **CMV-RNA kinetics in allo-HSCT patients: optimizing viral surveillance during and after letermovir prophylaxis**

C. Tramontozzi[1], L. Piermatteo[1], G. Torre[1], P. Paba[2], B. Mariotti[3], V. Malagnino[4], L. Campogiani[4], A. Bertoli[2], S. D'Anna[1], I. Grossi[1], A. Magnapera[1], G. De Angelis[3], G. Ciangola[3], S. Grelli[2], L. Sarmati[4], R. Cerretti[3], A. Venditti[3,5], R. Salpini[1], V. Svicher[1]

[1]Department of Biology, University of Rome Tor Vergata, Rome, Italy, [2]AOU Policlinico Tor Vergata, Rome, Italy, [3]Department of Onco-Hematology, Policlinico Tor Vergata Foundation, Rome, Italy, [4]Infectious Diseases Unit, Policlinico Tor Vergata Foundation, Rome, Italy, [5]Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy

21/05/2026 16.10-17.10 Lives, stigma and risk: social realities of sexual health and prevention — Sala Cassiopea 2

OC 19 **HIV care trajectories among transgender and cisgender migrants in a setting with strong community support: a 10-year monocentric study in Tuscany, Italy**

M. Maruotto[2], S. Trevisan[2], C. Malcontenti[1], M. Trotta[1], V. Donini[1], B. Borchi[1], P. Corsi[1], M. Pozzi[1], C. Fiorelli[1], A. Farese[1], I. Campolmi[1], G. Sterrantino[2], A. Bartoloni[2], F. Lagi[1]

[1]Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy, [2]Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

OC 20 **"Narrating to transform": stigma, coping, and the reshaping of life trajectories from diagnosis to disclosure among women with HIV**

S. Bergamo[1], F. Ferrami[1], F. Sabbatini[2], G. Giupponi[3], V. Cogliandro[2], N. Squillace[2], P. Bonfanti[4], F. Gaspani[1], A. Soria[2]

[1]Department of Sociology and Social Research, University of Milano-Bicocca, Milan, Italy, [2]Clinic of Infectious Diseases, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, [3]LILA, Como, Italy, [4]School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy

OC 21 **Chemsex Practices and Behavioral Determinants Among PrEP Users in the Italian PrIDE Cohort**

C. Fusetti[1], D. Moschese[1], G. Frate[2], G. Micheli[2], E. Caruso[3], A.M. Lucchini[4], A.R. Raccagni[5], C. Tincati[6], S. Lazzarin[1], D. Farinacci[2], M. Cernuschi[3], S. Nozza[5], V. Mazzotta[2]
[1]Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Italy, [2]National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, [3]Milano Checkpoint ETS, Milan, Italy, [4]CeMuSS (Multidisciplinary Sexual Health Center), ASL Città di Torino, Turin, Italy, [5]Infectious Diseases Unit, Vita Salute San Raffaele University, Milan, Italy, [6]Clinic of Infectious Diseases and Tropical Medicine, ASST Santi Paolo e Carlo, Milan, Italy

OC 22 **Chemsex and MDPV: assessing needs related problematic chemsex to provide comprehensive services**

A. Bianchi[1], P.L. Vinti[1], A. Antonino[1], C. Soligo[1], P.M. Testoni[1], M. Manfredini[1], G. Fracca[1], D. Zagato[1], M. Cernuschi[1,2]
[1]ASA ODV, Milano, Italy, [2]San Raffaele Hospital, Milano, Italy

21/05/2026 17.15-18.40 Expanding PrEP horizons: gender, age and community engagement in HIV prevention

Sala Pegaso 2

OC 23 **PrEP beyond 50: baseline profile and PrEP strategies of older users in the Italian PRIDE cohort**

A. Russo[1,2], R. Lolatto[3], A. Giacinta[4], G. Bozzi[5], E. Caruso[6], A.R. Raccagni[7], R.F. Del Vecchio[8], C. Fusetti[9], A. Guida[10], A.M. Lucchini[11], A. Renzani[12], G. Ancona[13], S. Cerere[14], P. Vassalini[15], V.L. Del Negro[16], A. Cattelan[17], M. Cernuschi[18], V. Mazzotta[19], S. Nozza[7,20]
[1]Link Campus University, Rome, Italy, [2]Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy, [3]Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy, [4]National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, [5]Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, [6]Milano Checkpoint ETS, Milan, Italy, [7]Infectious Diseases Unit, Vita-Salute San Raffaele University, Milan, Italy, [8]UOC Malattie infettive, PO Umberto I ASP Siracusa, Siracusa, Italy, [9]Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy, [10]PO Cotugno, AORN dei Colli, Naples, Italy, [11]Azienda Sanitaria Locale "Città di Torino", Turin, Italy, [12]S.C. Malattie Infettive, IRCCS San Gerardo dei Tintori, Monza, Italy, [13]Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Italy, [14]BLQ Checkpoint, Bologna, Italy, [15]Infectious Disease Unit, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy, [16]Checkpoint Plus Roma, Rome, Italy, [17]Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy Project and Clinical Research Unit, Padua University Hospital, Padua, Italy, [18]A.S.A. Onlus - Association of Solidarity AIDS, Milan, Italy, [19]Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy, [20]Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

OC 24 **Cumulative HIV vulnerability and PrEP engagement among cisgender women accessing a community-based testing service**

L. Nekrasova[1], L. Cavallero[1], E. Caruso[1], D. Zagato[1], R. Repossi[1], I. Gotti[1], P. Russo[1], P. Vinti[1], D. Moschese[1,2], V. Iannone[1,2], R. Rossotti[1,5], M. Cernuschi[1,4], N. Frattini[1]
[1]Milano Checkpoint ETS, Milan, Italy, [2]ASST Fatebenefratelli-Sacco, Milan, Italy, [3]ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, [4]San Raffaele Scientific Institute, Milan, Italy, [5]ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

OC 25 **Identifying the Eligibility Gap for Long-Acting Injectable PrEP in the Italian PrIDE Cohort**

D. Moschese[1], S. Nozza[2], S. Leone[3], S. Cecere[4], E. Caruso[5], G.C. Marchetti[6], R. Esvan[7], A.R. Raccagni[2], G. Frate[3], M. Tutone[8], M. Cernuschi[9], A. Gori[1], A. Antinori[7], A. Castagna[2], V. Mazzotta[7]
[1]Luigi Sacco University Hospital, ASST Fatebenefratelli Sacco, Milan, Italy, [2]San Raffaele Vita-Salute University, Milan, Italy, [3]Fondazione ICONA, Milan, Italy, [4]Plus Onlus, Bologna, Italy, [5]Milano Checkpoint ETS, [6]Universita degli Studi di Milano, Milan, Italy, [7]Lazzaro Spallanzani National Institute for Infectious Diseases, Rome, Italy, [8]ASL Città di Torino, [9]ASA Milano, Milan, Italy

OC 26 **Proportion of days covered by Long-Acting Cabotegravir versus Oral PrEP in the Italian PrIDE cohort**

V. Mazzotta[1], S. Nozza[2], S. Leone[1], G. Frate[3], D. Farinacci[1], E. Caruso[4], A.R. Raccagni[2], A. Lucchini[5], G.C. Marchetti[6], A.M. Cattelan[7], M. Tutone[5], V.L. del Negro[8], R. Rossotti, C. Tincati[6], C. Mussini[10], M. Cernuschi[4], A. Gori[11], A. Castagna[2], A. Antinori[1], D. Moschese[11]
[1]INMI L Spallanzani IRCCS- Roma, Italy, [2]Ospedale San Raffaele, Università Vita-Salute - Clinica Malattie Infettive - Milano, Italy, [3]Fondazione ICONA, Italy, [4]Milano Checkpoint, Italy, [5]Azienda Sanitaria Locale "Città di Torino", Torino, Italy, [6]ASST Santi Paolo e Carlo, Milan, Italy, [7]University Hospital of Padova, Padua, Italy, [8]PLUS Roma, Italy, [9]ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, [10]Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy, [11]Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy

OC 27 **Missed Opportunities for Doxy-PEP Use Among Individuals at Risk: A Cross-Sectional Study within the PRIDE Cohort**

A. De Vito[1], R. Lolatto[2], E. Caruso[3], G. Micheli[4], A.R. Raccagni[5], D. Tesoro[6], A.M. Lucchini[6], A. Gizzi[7], L.V. Del Negro[8], J. Testa[9], M. Menozzi[10], L. Pipitò[11], A.M. Cattelan[12], S. Cerere[13], M. Merelli[14], G. Ancona[6], D. Moschese[15], M. Cernuschi[16], V. Mazzotta[4], S. Nozza[17], R. Rossotti[18]
[1]Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, [2]PRIDE Cohort, Italy, [3]Associazione Milano Check Point – Milano, Italy, [4]U.O.C. Immunodeficienze Virali e IST, INMI "L. Spallanzani" IRCCS – Roma, Italy, [5]Ospedale San Raffaele, Università Vita-Salute - Clinica Malattie Infettive - Milano, Italy, [6]U.O.C. di Malattie Infettive e Tropicali, Presidio San Paolo – ASST Santi Paolo e Carlo – Milano, Italy, [7]Unit of Infectious Diseases, A.R.N.A.S Civico, Palermo, Italy, [8]Roma Check Point – Roma, Italy, [9]Unità Complessa di Malattie Infettive, ASST Valle Olona, Busto Arsizio, Italy, [10]Università degli Studi di Modena e Reggio Emilia, Modena – Clinica di Malattie Infettive e Tropicali - Modena, Italy, [11]Unit of Infectuous Diseases, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy, [12]Azienda Ospedaliera di Padova - U.O.C. Malattie Infettive – Padova, Italy, [13]BLQ Check Point – Bologna, Italy, [14]Infectious Diseases Clinica, ASU FC, Udine, Italy, [15]Dipartimento Malattie Infettive - ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco – Milano, Italy, [16]Associazione Milano Check Point – Milano, Italy, [17]Clinica Malattie Infettive - Ospedale San Raffaele, Università Vita-Salute – Milano, Italy, [18]S.C. Malattie Infettive – ASST Grande Ospedale Metropolitano Niguarda – Milano, Italy

OC 28 **Characteristics of Cisgender and Transgender Women in PrIDE cohort, risk behaviours and stigma**

G. Micheli[1], D. Farinacci[1], R. Lolatto[2], C. Fusetti[3], E. Caruso[4], E. Bruzzesi[5], A. Lucchini[6], D. Tesoro[7], L. Taramasso[8], A. Raimondi[9], A.M. Cattelan[10], E. Milano[11], E. Zappulo[12], F. Conti[13], S. Venturelli[14], A. De Bona[7], A. Antinori[1], D. Moschese[3], S. Nozza[2], V. Mazzotta[1]
[1]National Institute "Lazzaro Spallanzani" IRCCS, Rome, Italy, [2]IRCCS Ospedale San Raffaele, Infectious Diseases Unit, Milan, Italy, [3]Department of Infectious Diseases, Luigi Sacco University Hospital, ASST Fatebenefratelli Sacco, Milan, Italy, [4]Milano Checkpoint, Milano, Italy, [5]Infectious Diseases Unit, Vita-Salute San Raffaele University, Milan, Italy, [6]"Amedeo di Savoia" Hospital, Unit of Infectious Diseases, Turin, Italy, [7]Infectious Diseases Unit, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy, [8]Infectious Diseases, San Martino Hospital Genoa, University of Genoa, Genoa, Italy, [9]Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, School of Medicine and Surgery, Milan, Italy, [10]Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, [11]Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area, Polyclinic of Bari, University Hospital Polyclinic, University of Bari, Bari, Italy, [12]Department of Clinical Medicine and Surgery, Infectious Diseases Unit, University of Naples Federico II, Naples, Italy, [13]Infectious Diseases Unit, ASST Lecco, Lecco, Italy, [14]Infectious Diseases Unit, ASST "Papa Giovanni XXIII", Bergamo, Italy

21/05/2026 17.15-18.40 PrEP, doxyPEP and beyond: the new challenges of STI prevention

Sala Pegaso 3

OC 29 **Incidence and predictors of first and subsequent bacterial sexually transmitted infections (STIs) among PrEP users in the Italian PrIDE Cohort**

D. Farinacci[1], P. Stolfi[1], R. Esvan[1], G. Frate[1], A.R. Raccagni[2], C. Fusetti[3], S. Lazzarin[3], A. Lucchini[4], M. Augello[5], V.L. Del Negro[6], A.M. Cattelan[7], S. Cerere[8], M. Menozzi[9], F.M. Fusco[10], M. Tutone[11], A. Antinori[1], M. Cernuschi[12], S. Nozza[2], D. Moschese[3], V. Mazzotta[1]
[1]National Institute "Lazzaro Spallanzani" IRCCS, Rome, Italy, [2]Infectious Diseases Unit, Vita-Salute San Raffaele University, Milan, Italy, [3]Department of Infectious Diseases, Luigi Sacco University Hospital, ASST Fatebenefratelli Sacco, Milan, Italy, [4]Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy, [5]Clinic of Infectious Diseases and Tropical Medicine, Department of Health Sciences, San Paolo Hospital, ASST Santi Paolo E Carlo, University of Milan, Milan, Italy, [6]Roma Checkpoint, Rome, Italy, [7]Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, [8]PLUS aps (BLQ Checkpoint), Bologna, Italy, [9]Clinic of Infectious Diseases, University Hospital of Modena, University of Modena and Reggio Emilia, Modena, Italy, [10]UOC Infezioni sistemiche e dell'Immunodepresso, PO "D. Cotugno", AO dei Colli, Napoli, Italy, [11]Ce.Mu.S.S., Department of Prevention - ASL Città di Torino, Turin, Italy, [12]Milano Checkpoint, Milan, Italy

OC 30 **DoxyPEP remains underutilised to exert its full protection: data from a cohort of PrEP users**

E. Caruso[1], C. Muccini[1,2], P. Russo[1], A. De Bona[1,3], D. Moschese[1,4], N. Frattini[1], L. Nekrasova[1], D. Tesoro[1,3], V. Iannone[1,4], P. Vinti[1], M. Cernuschi[1], R. Rossotti[1,5]
[1]Milano Checkpoint ETS, Milan, Italy, [2]San Raffaele Scientific Institute, Milan, Italy, [3]ASST Santi Paolo e Carlo, Milan, Italy, [4]ASST Fatebenefratelli-Sacco, Milan, Italy, [5]ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

OC 31 **Awareness of key prevention tools in sexual health: comparison of key groups from a cross-sectional survey during European Testing Week in Rome (Let's Test! Study)**

G. Micheli, R. Esvan, G. Frate, V. Barchi, F. Cannone, D. Farinacci, R. Speranza, R.J. Steiner, O. Bruzzi, A. Giacinta, S. Onori, A. Antinori, V. Mazzotta
National Institute for Infectious Diseases "Lazzaro Spallanzani"- IRCCS, Rome, Italy

OC 32 **HIV burden and testing patterns among patients with sexually transmitted infections: a 30-year real-world analysis**

M. Giuliani[1], C. Stingone[1], L. Gianserra[1], M. Zaccarelli[1], F. Pimpinelli[2], M. G. Donà[1], E. Giuliani[1], F. Di Tullio[1], A. Latini[1]
[1]STI/HIV Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy, [2]Microbiology and Virology, San Gallicano Dermatological Institute, IRCCS, Rome, Italy

OC 33 **Incident syphilis and immunovirological perturbations in virally suppressed people living with HIV: a real-world self-controlled cohort study**

E. Zappulo, G. Di Filippo, S. Mercinelli, M. Cotugno, S. Candilio, M. D'Amato, M.A. Landri, M. Silvitelli, I. Gentile
Department of Clinical Medicine and Surgery, Infectious Diseases Unit, University of Naples Federico II, Naples, Italy

OC 34 **Changes in MPOX clinical presentation across epidemic phases: a single-centre cohort study in Italy, 2022 -2026**

R.J. Steiner[1], P. Stolfi[2], V. Barchi[1], G. Frate[1], D. Farinacci[1], R. Esvan[1], L. Bordi[1], G. Micheli[1], A. Giacinta[1], R. Schiavone[1], N. Braccialarghe[1], G. De Carli[3], F. Vairo[3], F. Maggi[1], A. Antinori[1,4], V. Mazzotta[1]
[1]National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy, Regional AIDS Reference Center, Rome, Italy, [2]Institute for Applied Mathematics "Mauro Picone", National Research Council, Rome, Italy, [3]SERESMI, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, [4]Health Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy

21/05/2026 17.15-18.15 Real World Evidence: insights from Italian Cohorts — Sala Cassiopea 2

OC 35 Virological and Clinical Outcomes of PWH with and without Advanced HIV Disease and very high HIV-RNA at ART initiation: Data from the ICONA Foundation Cohort

A. Giacomelli[1,2], N. Lentini[3], A. Tavelli[4,5], A. Mondi[6], L. Taramasso[7], G. D'Ettorre[8], G.F. Pellicano[9], G. Madeddu[10], A. Di Biagio[7,11], E. Bruzzesi[12], V. Mazzotta[6], A. Antinori[6], S. Lo Caputo[13], C.F. Perno[14], A. d'Arminio Monforte[4], on behalf of ICONA Foundation Study Group - ICONA cohort

[1]Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy, [2]Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Milan, Italy, [3]Department of Life Sciences and Public Health, Section of Hygiene, Università Cattolica del Sacro Cuore, Rome, Italy, [4]ICONA Foundation, Milan, Italy, [5]Department of Public Health, Experimental and Forensic Medicine, National PhD Programme in One Health Approaches to Infectious Diseases and Life Science Research, University of Pavia, Pavia, Italy, [6]Clinical Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, [7]Infectious Disease Clinic, IRCCS Ospedale Policlinico San Martino, Genova, Italy, [8]Department of Public Health and Infectious Diseases, Sapienza Università di Roma, Rome, Italy, [9]Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, AOU Policlinico G. Martino, Messina, Italy, [10]Unit of Infectious Diseases, Department of Medicine, Surgery, and Pharmacy, University of Sassari, Sassari, Italy, [11]Department of Health Sciences, University of Genoa, Genoa, Italy, [12]Infectious Diseases Unit, Vita-Salute San Raffaele University, Milan, Italy, [13]Clinic of Infectious Diseases, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy, [14]Microbiology and Diagnostics of Immunology Unit, Multimodal Research Area, IRCCS Bambino Gesù Pediatric Hospital, Rome, Italy

OC 36 Durability of Bictegravir/Emtricitabine/Tenofovir alafenamide vs Dolutegravir-based single tablet regimens in a large Cohort of experienced PWH: the BIC-LASTING study

R. Gagliardini[1], A. Cozzi-Lepri[2], A. Tavelli[3,4], A. Saracino[5], V. Iannone[6], F. Conti[7], R. Corsini[8], V. Mazzotta[1], M.C. Poliseno[5], L. Albini[9], G. Forcina[9], A. Gori[10], A. Castagna[11], A. Antinori[1], A. d'Arminio Monforte[3], on behalf of the Icona Foundation Cohort

[1]National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, [2]Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK, [3]ICONA Foundation, Milan, Italy, [4]National PhD Programme in One Health approaches to infectious diseases and life science research, Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy, [5]Clinic of Infectious Diseases, Department of Precision Medicine and Jonian Area (DiMePre-J), University of Bari "Aldo Moro", Bari, Italy, [6]ASST Fatebenefratelli-Sacco, DIBIC Luigi Sacco, Milan, Italy, [7]Infectious Diseases Unit, Alessandro Manzoni Hospital, Lecco, Italy, [8]Infectious Disease Unit, Azienda USL-IRCCS di Reggio Emilia, Italy, [9]Gilead Sciences Srl, Italy, [10]II Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Department of Biomedical and Clinical Sciences L. Sacco, Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy, [11]Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy

OC 37 Legacy ART in the modern era: who still receives outdated regimens?

A. Vergori[1], A. Tavelli[2,3], A. Giacomelli[4], S. Rusconi[5], S. Nozza[6], A. Costantini[7], G. Lapadula[8], S. Bonora[9], G. Madeddu[10], R. Gagliardini[11], A. Antinori[11], A. d'Arminio Monforte[2], S. Lo Caputo[1]

[1]Infectious Diseases Unit, Department of Clinical and Surgical Sciences, University of Foggia, Foggia, Italy, [2]ICONA Foundation, Milan, Italy, [3]National PhD Programme in One Health approaches to infectious diseases and life science research, Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy, [4]III Infectious Diseases Unit, ASST Fatebenefratelli-Sacco, DIBIC Luigi Sacco, Università degli Studi di Milano, Milan, [5]Infectious Diseases Unit, Ospedale Civile di Legnano, ASST Ovest Milanese, and DIBIC, Università degli Studi di Milano, Milan, [6]Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, [7]Clinical Immunology Unit, Azienda Ospedaliero Universitaria delle Marche - Università Politecnica delle Marche, Ancona, Italy, [8]Department of Infectious Diseases, IRCCS San Gerardo dei Tintori, University of Milano-Bicocca, Monza, Italy, [9]Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy, [10]Unit of Infectious Disease, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, [11]Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy

OC 38 Long-term effectiveness and tolerability of cabotegravir plus rilpivirine as a switch strategy in a multicenter Italian real-world cohort

A. Ciccullo[1], G. Baldin[2], A. Cervo[3], M.V. Cossu[4], S. Trevisan[5], A. De Vito[6], M. Fabbiani[7], E. Altavilla[8], E. Delmonte[3], M. Matone[4], F. Lagi[5], F. Bassani[9], P.F. Salvo[2], G. Madeddu[6], A. Borghetti[10], S. Rusconi[9], A. Giacomelli[3], C. Mussini[3], S. Di Giambenedetto[2,11]

[1]Infectious Diseases Unit, Ospedale San Salvatore, L'Aquila, Italy, [2]Infectious Diseases Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, [3]Department of Infectious Diseases, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy, [4]Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy, [5]Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, [6]Infectious Diseases Unit, University of Sassari, Sassari, Italy, [7]Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy, [8]Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, [9]Infectious Diseases Unit, ASST Ovest Milanese, Legnano, Italy, [10]Infectious Diseases Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, [11]Catholic University of the Sacred Heart, Rome, Italy

21/05/2026 17.40-18.40 Immuno and inflammology markers in translational research — Sala Antares

OC 39 A 3D airway epithelium-monocyte co-culture model to assess the impact of CCR2 and CCR5 inhibition on SARS-CoV-2 replication and inflammatory responses

C. Antonucci, M. Andreotti, Z. Michelini, C.M. Galluzzo, R. Amici, A. Eramo, G. Castelli, S. Lo Cicero, A.M. Cerio, S. Cecchetti, F. Spadaro, R. Bona, M.C. Gauzzi, L. Fantuzzi
Istituto Superiore di Sanità, Rome, Italy

OC 40 **Ultra-low level soluble p24 production identifies an IP-10-dominant inflammatory signature linked to physiologic frailty and mortality risk in virologically suppressed people with HIV**

M. Augello[1], A. Mingione[2], C. Orlandi[3], R. Rovito[1], V. Bono[1], V. Sala[1], C. Tincati[1], F. Martinelli Boneschi[2], A. Casabianca[3], G. Marchetti[1]
[1]Clinic of Infectious Diseases and Tropical Medicine, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, [2]Clinic of Neurology, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, [3]Department of Biomolecular Sciences, University of Urbino "Carlo Bo", Urbino, Italy

OC 41 **Long-Term Follow-Up to 96 Weeks of Long-Acting Cabotegravir/Rilpivirine: Sustained Reduction of Immune Activation and Senescence in People living with HIV and CMV Co-Infection**

M. Guardiani[3], F. Dominelli[1], E. Tortellini[1], A. Carraro[1], L. Ansaldo[2], M.A. Zingaropoli[1], M. Proietti[1], M. Antonacci[1], F. Mengoni[1], G. Mancarella[2], A. Gasperin[2], M. De Masi[2], S. Vita[3], C.M. Mastroianni[1], R. Marocco[2], C. Del Borgo[2], M. Lichtner[3]
[1]Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, [2]Infectious Diseases Unit, SM Goretti Hospital, Sapienza University of Rome, Latina, Italy, [3]Department of Neurosciences, Mental Health, and Sense Organs, NESMOS, Sapienza University of Rome, Rome, Italy

OC 42 **Immunometabolic remodeling, not response magnitude, distinguishes acute from chronic HIV Infection**

D. Lo Tartaro[1], E. Santacroce[1], N. Paschalidis[2], A.L. Ciobanu[1], E. Serattini[1], L. Gibellini[1], M. Menozzi[3], C. Mussini[3], A. Cossarizza[1,4], S. De Biasi[1]
[1]Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia School of Medicine, Modena, Italy, [2]Biomedical Research Foundation Academy of Athens, Athens, Greece, [3]Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy, [4]National Institute for Cardiovascular Research, Bologna, Italy

22/05/2026 10.05-11.05 Success comes at a cost: weight, lipids and metabolic risks in HIV — Sala Antares

OC 43 **The choice of first-line ART class is not associated with differential weight gain in people who are already obese or overweight**

L. Costacurta[1], L. Taramasso[2], E. Ricci[3], N. Squillace[4], G. Orofino[5], G.F. Pellicanò[6], G.V. De Socio[7], B. Menzaghi[8], S. Ferrara[9], P. Maggi[10], P. Bonfanti[4], A. Di Biagio[1,2], on behalf of CISAI Study Group
[1]Department of Health's Sciences, University of Genoa, Genoa, Italy, [2]Infectious Diseases Clinic, IRCCS Azienda Ospedaliera Metropolitana, Genoa, Italy, [3]Fondazione ASIA Onlus, Buccinasco (MI), Italy, [4]Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, University of Milano-Bicocca, Monza, Italy, [5]Division of Infectious and Tropical Diseases, ASL Città di Torino, Italy, [6]Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, AOU Policlinico G. Martino, Messina, Italy, [7]Clinic of Infectious Diseases, Department of Medicine and Surgery, University of Perugia, Italy, [8]Unit of Infectious Diseases, ASST della Valle Olona – Busto Arsizio (VA), Italy, [9]Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy, [10]Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy

OC 44 **Obesity at antiretroviral therapy initiation and long-term risk of cardiovascular disease, cancer, or death in people with HIV: a prospective cohort study**

C. Mussini[1], A. Giacomelli[2,3], G. Lapadula[4,5], A. Di Biagio[6,7], A. Gori[2,3], G. Orofino[8], E. Quiros-Roldan[9], A. Cingolani[10], G. Madeddu[11], V. Mazzotta[12], R. Rossotti[13], S. Lo Caputo[14], G. Marchetti[15], J. Chester[16], A. d'Arminio Monforte[17], G. Guaraldi[1], A. Cozzi-Lepri[18], on behalf of the ICONA Foundation Study Group - ICONA cohort
[1]Infectious Diseases Unit, Azienda Ospedaliero-Universitaria Policlinico di Modena; University of Modena and Reggio Emilia, School of Medicine, Modena, Italy, [2]Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Milano, Italy, [3]Department of Infectious Diseases, ASST Fatebenefratelli Sacco, "L. Sacco" University Hospital, Milan, Italy, [4]Infectious Diseases Unit, IRCCS San Gerardo dei Tintori, Monza, Italy, [5]University of Milano-Bicocca, Monza, Italy, [6]Infectious Diseases Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, [7]Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, [8]Division I of Infectious and Tropical Diseases, ASL Città di Torino, Torino, Italy, [9]Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Ospedali Civili di Brescia, Brescia, Italy, [10]Unit of Infectious Diseases, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Department of Safety and Bioethics, Università Cattolica del Sacro Cuore, Rome, Italy, [11]Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, [12]Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy, [13]Clinic of Infectious Diseases, University of Verona, Verona, Italy, [14]Clinic of Infectious Diseases, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy, [15]Clinic of Infectious Diseases and Tropical Medicine, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, [16]Department of Surgical, Medical, Dental and Morphological Sciences Related to Transplant Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy, [17]Icona Foundation, Milan, Italy, [18]Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK

OC 45 **Statin Therapy for Primary and Secondary Prevention in People With HIV: Gaps and Achievements in a Real-Life Setting**

G. Torkjazi[1,2], R. Papaioannu Borjesson[1], N. Capra[1], R. Lolatto[1], C. Muccini[1], S. Nozza[1,2], D. Canetti[1], T. Clemente[1], E. Bruzzesi[1], H. Hasson[1], A. Castagna[1,2], V. Spagnuolo[1,2]
[1]IRCCS San Raffaele Scientific Institute, Infectious Diseases Department, Milan, Italy, [2]Vita-Salute San Raffaele University, Milan, Italy

OC 46 **Impact of Rosuvastatin vs. Atorvastatin on Insulin Resistance and Diabetes Mellitus in People With HIV**

J. Milic[1], A. Carobbio[2], M. Menozzi[1,3], M. Manicardi[4], G. Cuomo[3], G. Mancini[3], M. Belli[1], T. Albano[1], M. Ricciardetto[1], I. Avanzini[1], E. Delmonte[1], L. Gozzi[1], P. Raggi[5], C. Mussini[1,3], G. Guaraldi[1,3]
[1]Modena HIV Metabolic Clinic, University of Modena and Reggio Emilia, Modena, Italy, [2]Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy, [3]Infectious Diseases Clinic, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy, [4]Cardiology Division, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy, [5]Department of Medicine and Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada

22/05/2026 10.05-11.05 Next Generation Sequencing (NGS): redefining management of chronic viral infections

Sala Cassiopea 2

OC 47 Evaluation of a NGS Assay for detecting HIV1 proviral drug resistance mutations: association with total HIV-1 DNA levels and with historical genotype resistance test

T. Allice, F. Cerutti, G. Gregori, M.G. Milia, E. Burdino, B. Simoncelli, S. Monteleone, M. Cazzadore, A. Bottoni, E. Scuccimarra, V. Ghisetti
Laboratory of Microbiology and Virology, ASL Città di Torino, Torino, Italy

OC 48 Comparison between Next-Generation Sequencing and Historical Genotypic Resistance Testing at Virological Failure in ART-Experienced Individuals: Data from the ARCA Cohort and the Italian NGS Network

D. Armenia[1], V. Micheli[2], V. Ricucci[3], A. De Vito[4], M. Sambo[5], A. Bezenchek[6,7], O. El Khalili[8], B. Bruzzone[3], W. Gennari[9], E.G. Arosio[10], I. Giovannelli[11], G. Massobrio[12], M. Menozzi[13], B. Rossetti[14], F. Ceccherini-Silberstein[8], M.M. Santoro[8]
[1]UniCamillus, Saint Camillus International University of Health Sciences, Rome, Italy, [2]Clinical Microbiology, Virology and Bioemergency Diagnostics, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy, [3]Hygiene Unit, IRCCS Azienda Ospedaliera Metropolitana - Genova, Italy, [4]Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, [5]Infectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria Senese, Siena, Italy, [6]IPRO-InformaPRO S.r.l., Rome, Italy, [7]EuResist Network GEIE, Rome, Italy, [8]Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy, [9]Molecular Microbiology and Virology Unit, Azienda Ospedaliero Universitaria di Modena, Modena, [10]Microbiology and Virology Unit, ASST Papa Giovanni XXIII, Bergamo, [11]Clinical Immunology, Allergy and Advanced Biotechnologies Unit, AUSL - IRCCS Reggio Emilia, Reggio Emilia, Italy, [12]Infection disease Unit, IRCCS - Policlinico San Martino Hospital, Genoa, Italy, [13]Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy, [14]Infectious Diseases Unit, Azienda USL Toscana sud-est, Ospedale Misericordia, Grosseto, Italy

OC 49 Added value of RNA-based whole genome sequencing in viremic people with 4-class drug-resistant HIV: insights from the PRESTIGIO Registry

T. Clemente[1], S. Sisti[2,3], B. Menzaghi[4], M. Feasi[5], M. Fabbiani[6], R. Lolatto[1], M. Sampaolo[3], L. Calza[7], R. Gagliardini[8], S. Bonora[9], M.M. Santoro[10], M. Zazzi[11], V. Spagnuolo[1,2], N. Clementi[2,3], on behalf of the PRESTIGIO Study Group
[1]Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, [2]Vita-Salute San Raffaele University, Milan, Italy, [3]Laboratory of Microbiology and Virology, IRCCS San Raffaele Scientific Institute, Milan, Italy, [4]Unit of Infectious Diseases, ASST Della Valle Olona-Busto Arsizio, Busto Arsizio, Italy, [5]Department of Infectious Diseases, E.O. Ospedali Galliera, Genoa, Italy, [6]Department of Medical Biotechnologies, Infectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria Senese, University of Siena, Siena, Italy, [7]Infectious Diseases Unit, IRCCS Policlinico di Sant'Orsola, Alma Mater Studiorum University of Bologna, Bologna, Italy, [8]Clinical and Research Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, [9]Unit of Infectious Diseases, Amedeo di Savoia Hospital, Department of Medical Sciences, University of Turin, Turin, Italy, [10]Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, [11]Department of Medical Biotechnology, University of Siena, Siena, Italy

OC 50 Genetic diversity in hepatitis Delta antigen and ribozyme is associated with altered virological and biochemical markers and could help identify novel therapeutic targets

S. D'Anna[1], A. Magnapera[1], L. Piermatteo[1], T. Annamuhammedova[1], L. Fabeni[2], G. Torre[1], L. Carioti[1], E.L. Lebomo Etogo[3], A. Bertoli[1,4], P. Paba[4], A. Olivero[5], E. Teti[6], A. Di Lorenzo[6], V. Malagnino[6], M. Iannetta[6], L. Baiocchi[7], S. Francioso[7], I. Lenci[7], M. Arosio[8], M. Totaro[8], T. Santantonio[9], N. Randazzo[10], B. Bruzzone[10], U. Cillo[11], A. Vitale[11], G. Brancaccio[12], G.B. Gaeta[13], A. Ciancio[5], F. Ceccherini-Silberstein[1], S. Grelli[1,4], L. Sarmati[6], P. Lampertico[14], M. Rizzetto[5], G.P. Caviglia[5], R. Salpini[1], V. Svicher[1]
[1]University of Rome "Tor Vergata", Rome, Italy, [2]National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy, [3]Douala Gyneco-Obstetric and Pediatric Hospital, Douala, Cameroon, [4]Policlinico Universitario Tor Vergata, Rome, Italy, [5]University of Turin, Turin, Italy, [6]Infectious Disease Clinic, Policlinico Universitario Tor Vergata, Rome, Italy, [7]Hepatology Unit, Policlinico Universitario Tor Vergata, Rome, Italy, [8]Microbiology and Virology Unit, ASST "Papa Giovanni XXIII", Bergamo, Italy, [9]Infectious Diseases Unit, University of Foggia, Foggia, Italy, [10]University of Genoa, Genoa, Italy, [11]Hepatobiliary Surgery and Liver Transplantation Unit, Oncology and Gastroenterology, University of Padova, Padua, Italy, [12]Link Campus University Rome, Rome, Italy, [13]Infectious Disease Unit, University L. Vanvitelli, Naples, Italy, [14]Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

22/05/2026 12.15-13.15 Exploring the unseen: Low-Level Viremia, Immune activation and ART outcomes

Sala Antares

OC 51 Persistent low-level viremia is not associated with increased risk of serious clinical outcomes in the contemporary INSTI era: a time-updated analysis

G. Festa[1], R. Patanè[1], N. Capra[2], R. Lolatto[2], G. Loi[1], G. Torkjazi[1], G. Catalano[1], H. Hasson[2], S. Nozza[1,2], A. Castagna[1,2], V. Spagnuolo[1,2], T. Clemente[2]
[1]Vita-Salute San Raffaele University, Milan, Italy, [2]Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy

OC 52 GREENWOOD study: viroloGic contRol achiEvemENt sWitching frOm 2drs tO 3Drs

R. Rossotti[1], N.B. Bana[1], M.C. Moioli[1], F. D'Amico[1], G. Cavazza[1,2], E. Di Gennaro[1,2], A. Forni[1,2], L. Luzi[1,2], G.J. Burastero[1], L.F. Rezzonico[1], F. Peracchi[1,2], M. Puoti[1,2]
[1]ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, [2]School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy

OC 53 Long-Acting Cabotegravir/Rilpivirine Beyond Viral Suppression: Effects on HIV Reservoir, Immune Activation and Senescence

L. Maddaloni[1], L. De Martino[2], Z. Michelini[3], G. Bugani[2], L. Santinelli[2], C. Falvino[2], A. Lazzaro[2], R. Donà[2], L. Bortolani[2], M. Andreotti[3], G. Antonelli[1], C. Mastroianni[2], C. Scagnolari[1], G. d'Ettorre[2]
[1]Department of Molecular Medicine, University of Rome La Sapienza, Rome, Italy, [2]Department of Public Health and Infectious Diseases, University of Rome La Sapienza, Rome, Italy, [3]National Center for Global Health, Istituto Superiore di Sanità, Rome, Italy

OC 54 **Two-Year Immunological and Neuroinflammatory Outcomes of Switching to Long-Acting Cabotegravir/Rilpivirine in PLWH**
M.A. Zingaropoli[1,2], M. Guardiani[1], A. Carraro[1], F. Dominelli[1], M. Antonacci[1], M. Proietti[1], C. Del Borgo[3], E. Tortellini[1], R. Marocco[3], G. Mancarella[1], L. Ansaldo[3], O. Turriziani[1], M.R. Ciardi[1], C.M. Mastroianni[1], M. Lichtner[1]
[1]Sapienza University of Rome, Rome, Italy, [2]University Hospital Policlinico Umberto I, Sapienza University of Rome, Rome, Italy, [3]SM Goretti Hospital, Sapienza University of Rome, Latina, Italy

22/05/2026 12.15-13.15 Stigma, knowledge and behaviours in the era of HIV prevention

Sala Cassiopea 2

OC 55 **Knowledge reduces stigma: the results of the #cHIVuoleconoscere project**
C. Pellegris[1], P. Meli[1], I. Mercurio[1], V. Gotti[1], F. Gritti[1], E. Zanetti[1], F. Maggiolo[1], I. Fontana[2]
[1]Cooperativa Don Giuseppe Monticelli/Bergamo Fast-track City Network, Bergamo, Italy, [2]Ufficio scolastico provinciale di Bergamo/Bergamo Fast-track City Network, Bergamo, Italy

OC 56 **Effectiveness and sustainability of organisational models for delivering comprehensive sexuality education in Italian secondary schools: a two-year analysis, 2023-2025**
A. Chinelli[1], G. Paparatto[1], P. Giangrande[2], M. Farinella[3], C. Celata[4], M. Ubbiali[5], D. Martinelli[6], L. Tavoschi[1]
[1]Department of Translational Research and New Medical and Surgical Technologies, University of Pisa, Pisa, Italy, [2]Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, [3]Italian National Association for the Fight Against Aids (ANLAIDS), Rome, Italy, [4]Department of Prevention, General Directorate of Welfare, Regione Lombardia, Milan, Italy, [5]Department of Human Sciences, University of Verona, Verona, Italy, [6]Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy

OC 57 **Comprehensive sexuality education in secondary schools 2025-2026**
P. Testoni[1], C. Soligo[1], P. Vinti[1], F. Rossi[1], A. Bianchi[1], D. Zagato[1], M. Cernuschi[2]
[1]ASA Associazione Solidarietà AIDS ODV, Milano, Italy, [2]San Raffaele Hospital, Milano, Italy

OC 58 **Beyond diversity: The Impact of a Multi-Stakeholder Network on the Right to Health**
I. Mercurio[1], P. Meli[1], V. Gotti[1], F. Gritti[1], C. Pellegris[1], E. Zanetti[1], R. Carissoli[2], M. Rizzi[3], M. Beretta[3], F. Maggiolo[4], S. Venturelli[5], L. Comi[5], M. Deghi[6], C. Castelli[6]
[1]Cooperativa Don Giuseppe Monticelli/Bergamo FTC Network, Bergamo, Italy, [2]Arcigay Bergamo Cives/Bergamo FTC Network, Bergamo, Italy, [3]Croce Rossa Italiana – Comitato di Bergamo, Bergamo, Italy, [4]Bergamo Fast Track City, Bergamo, Italy, [5]ASST Papa Giovanni XXIII, Bergamo, Italy, [6]CICA, Milano, Italy

22/05/2026 14.00-15.00 Living longer, facing more: cancer and the persistent burden of late HIV diagnosis

Sala Pegaso 3

OC 59 **Trends and risk factors for late HIV diagnosis in Italy from 2012 to 2024**
V. Regine, L. Pugliese, B. Suligoi
Department of Infectious Diseases, National Institute of Health, Rome, Italy

OC 60 **More than doubled risk of virus-related non-AIDS-defining cancers in people with multidrug-resistant HIV: a matched multicohort analysis**
T. Clemente[1], N. Capra[1], L. Oreni[2], R. Lolatto[1], G. Pozza[2], S. Di Giambenedetto[3,4], C. Fornabaio[5], E. Fronti[6], D. Distefano[7], M. Matone[2], F. Lagi[8], A. Cervo[9], V. Spagnuolo[1,7], A. Giacomelli[2,10], on behalf of the PRESTIGIO Study Group
[1]Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, [2]Department of infectious diseases, ASST Fatebenefratelli Sacco, Milan, Italy, [3]Infectious Diseases Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, [4]Catholic University of the Sacred Heart, Rome, Italy, [5]Infectious Diseases Unit, ASST Cremona, Cremona, Italy, [6]Unit of Infectious Diseases, AO-Universitaria, Parma, Italy, [7]Vita-Salute San Raffaele University, Milan, Italy, [8]Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, [9]Department of Infectious Diseases, Azienda Ospedaliero-Universitaria di Modena, Policlinico di Modena, Modena, Italy, [10]Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Milan, Italy

OC 61 **Trends in age at cancer diagnosis and cancer type distribution in people with HIV from 2008 to 2025**
G. Loi[1], N. Capra[2], R. Lolatto[2], E. Bruzzesi[2], H. Hasson[2], S. Bossolasco[2], V. Spagnuolo[1,2], S. Nozza[1,2], A. Castagna[1,2], C. Muccini[2]
[1]Vita-Salute San Raffaele University, Milan, Italy, [2]IRCCS San Raffaele Scientific Institute, Milan, Italy

OC 62 **Real-world impact of IANS recommendations on anal cancer screening practices**
E. Bruzzesi[1], N. Capra[1], R. Lolatto[1], C. Candela[2], A.R. Raccagni[2], G. Ponta[1], T. Clemente[1], A.M. Tamburini[3], A. Castagna[1,2], S. Nozza[1,2]
[1]Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy, [2]Vita-Salute San Raffaele University, Milan, Italy, [3]Gastrointestinal Surgery Unit, San Raffaele Scientific Institute, Milan, Italy

22/05/2026 14.00-15.00 Connecting the dots: cardiovascular, renal and metabolic risk in HIV

Sala Antares

OC 63 **Independent predictors of major cardiovascular events (MACEs) in People Living with HIV (PLWH) before and after 2015: a matched case–control analysis**
P.F. Salvo[1,2], F. Lombardi[1,2], A. Carbone[1,2], G. Baldin[1,2], G. Lenzi[2], C. De Vivo[2], S. Colaiuda[2], F. La Fata[2], G. Cucinotta[2], C. Torti[1,2], S. Di Giambenedetto[1,2]
[1]Dipartimento di Scienze Mediche e Chirurgiche, UOC Malattie Infettive, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Roma, Italy, [2]Dipartimento di Sicurezza e Bioetica, sezione Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy

OC 64 **Prevalence and long-term transitions of cardiovascular-kidney-metabolic syndrome stages in PWH**

J. Milic[1], C. Puzzolante[2], L. Gozzi[2], M. Menozzi[2], F. Cinque[3], G. Cuomo[2], G. Mancini[2], R. Lombardi[3], C. Mussini[1,2], G. Sebastiani[4], G. Guaraldi[1,2]
[1]Clinic for Infectious Diseases, University Hospital of Modena, Modena, Italy, [2]Modena HIV Metabolic Clinic, University of Modena and Reggio Emilia, Modena, Italy, [3]Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, [4]Division of Gastroenterology and Hepatology, and Chronic Viral Illness Service, McGill University Health Centre, Montreal, Canada

OC 65 **Endocrine and Metabolic Alterations in Aging PLWH with Low Bone Mineral Density**

V. Bono[1], C. Tincati[1], M. Augello[1], R. Rovito[1], A.M. Previtera[2], V. Sala[1], F. Monti[1], M. Cozzolino[3], P. Ciceri[3], G. Marchetti[1]
[1]Clinic of Infectious Diseases and Tropical Medicine, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, [2]Rehabilitation Unit, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, [3]Renal Division, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy

OC 66 **Statin use and tolerability in a multicenter Italian cohort of people with HIV**

A. Bailoni[1,2], G. Carrozzo[3], A. Cervo[4], B. Rossetti[5], F. Lagi[6], M. Sambo[1,2], B. Caloni[3], M. Ricciardetto[4], C. Nencioni[5], V. Donini[7], A. Gori[3,8], M. Tumbarello[1,2], A. Giacomelli[3,8], M. Fabbiani[1,2]
[1]University of Siena, Siena, Italy, [2]Azienda Ospedaliero-Universitaria Senese, Siena, Italy, [3]ASST Fatebenefratelli Sacco, Milan, Italy, [4]University Hospital of Modena, Modena, Italy, [5]Misericordia Hospital, Grosseto, Italy, [6]Azienda Ospedaliero-Universitaria Careggi, Florence, Italy, [7]University of Florence, Florence, Italy, [8]University of Milan, Milan, Italy

22/05/2026 Switch for a Long-Term Success

Sala Pegaso 3

15.05-16.05

OC 67 **Reasons for discontinuation of single-tablet regimen rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF) in the era of 2nd-generation INSTIs**

D. Ripamonti[1], L. Comi[1], D. Valenti[2], A. Cargnelutti[3], M.V. Cossu[4], A. Poloni[4], A. Giacomelli[4,5], G. Lapadula[6], L. Mezzadri[6], P. Bonfanti[6], M. Mazzitelli[7], A. Cattelan[7], R. Gulminetti[8], L. Pagnucco[8], A. Celsi[8], S. Rapino[9], B. Fioretti[9], A. Francavilla[2], E. Foca[9]
[1]Infectious Diseases Unit, ASST Papa Giovanni XXIII, Bergamo, Italy, [2]FROM-Fondazione per la Ricerca Ospedale di Bergamo-ETS, Bergamo, Italy, [3]School of Medicine and Surgery, University of Milan, Milan, Italy, [4]Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milano, Italy, [5]Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Milan, Italy, [6]IRCCS Fondazione San Gerardo dei Tintori, University of Milano Bicocca, Monza, Italy, [7]Infectious and Tropical Diseases Unit, Department of Molecular Medicine, Padua University Hospital, Padova, Italy, [8]Department of Medical Science and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy, [9]Department of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy

OC 68 **Clinical outcomes in PWH switching from oral combinations with dolutegravir (DTG) + lamivudine (3TC) or rilpivirine (RPV) to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF): data from the Italian ICONA Foundation Cohort (OPTIMIZE-BIC Analysis)**

A. De Vito[1], A. Tavelli[2,3], A. Giacomelli[4,5], V. Mazzotta[6], G. Orofino[7], R. Serraino[8], R. Marocco[9], R. Rossotti[10], S. Nozza[11], L. Albini[12], G. Forcina[12], A. Vergori[13], A. Di Biagio[14,15], A. d'Arminio Monforte[2], G. Madeddu[1]
[1]Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, [2]Fondazione ICONA, Milan, Italy, [3]National PhD Programme in One Health Approaches to Infectious Diseases and Life Science Research, Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy, [4]Department of Infectious Diseases, Luigi Sacco University Hospital, ASST Fatebenefratelli Sacco, Milan, Italy, [5]Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, [6]U.O.C. Immunodeficienze Virali e IST, INMI "L. Spallanzani" IRCCS – Roma, Italy, [7]Unit of Infectious Diseases, "Divisione A", ASL "Città di Torino", Torino, Italy, [8]Dipartimento di Sicurezza e Bioetica - Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy, [9]Infectious Diseases Unit, SM Goretti Hospital, Latina, Italy, [10]S.C. Malattie Infettive – ASST Grande Ospedale Metropolitano Niguarda – Milano, Italy, [11]Clinica Malattie Infettive - Ospedale San Raffaele, Università Vita-Salute – Milano, Italy, [12]Gilead Sciences Srl, Italy, [13]Infectious Diseases Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy, [14]Department of Health Sciences, University of Genoa, Genoa, Italy, [15]Infectious Disease Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

OC 69 **Tolerability and cardiovascular safety of DOR/3TC/TDF as a switch regimen after 144 weeks of observation in the DOROTEA study cohort**

A. Ciccullo[1], G. Baldin[2], A. Tommasi[3], A. Cervo[4], G. Formica[5], V. Iannone[6], M. Fabbiani[7], E. Altavilla[8], M. Menozzi[4], G. Madeddu[9], S. Colaiuda[10], F. Lagi[5], C. Papalini[3], D. Moschese[6], S. Di Giambenedetto[2,10]
[1]Infectious Diseases Unit, Ospedale San Salvatore, L'Aquila, Italy, [2]Infectious Diseases Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, [3]Department of Medicine and Surgery, Section of Infectious Diseases, University of Perugia, Perugia, Italy, [4]Department of Infectious Diseases, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy, [5]Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, [6]Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy, [7]Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy, [8]Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, [9]Infectious Diseases Unit, University of Sassari, Sassari, Italy, [10]Catholic University of the Sacred Heart, Rome, Italy

OC 70 **Switching antiretroviral therapy after weight gain: pro and cons from the ICONA Foundation cohort**

L. Taramasso[1], M. Muccio[1], N. Squillace[2], A. De Vito[3], M. Guastavigna[4], E. Quiros Roldan[5], C. Tincati[6], M. Fabbiani[7], N. Gianotti[8], M. Puoti[9], A. Cozzi-Lepri[10], G. Guaraldi[11], A. Di Biagio[1,12], on behalf of ICONA Foundation Study Group - ICONA cohort
[1]Infectious Diseases Clinic, IRCCS Azienda Ospedaliera Metropolitana , Genova, Italy, [2]Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza - University of Milano-Bicocca, Monza, Italy, [3]Unit of Infectious Disease, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, [4]S.C. Malattie Infettive e Tropicali I, ASL Città di Torino, Amedeo di Savoia Hospital, Turin, Italy, [5]Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy, [6]Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, [7]Infectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria Senese, Siena, Italy, [8]Icona Foundation, Milan, Italy, [9]Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, University of Milan-Bicocca, Milan, Italy, [10]Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK, [11]Department of Infectious Diseases, Azienda Ospedaliero-Universitaria di Modena, Policlinico di Modena, University of Modena and Reggio Emilia, Modena, Italy, [12]Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy

22/05/2026 15.05-16.05 Long-Acting Cabotegravir/Rilpivirine from different perspectives — Sala Antares

OC 71 Scaling long-acting cabotegravir/rilpivirine in routine HIV care: 48-Week implementation outcomes from the PROGRESS model

S. Di Giambenedetto[1,2], P.F. Salvo[1,2], A. Carbone[1,2], G. Cucinotta[1], F. Lombardi[1,2], E. Visconti[2], E. Tamburrini[1,2], G. Baldin[2], F. Pellegrini[3], A. De Belvis[4], C. Torti[1,2]

[1]Dipartimento di Scienze Mediche e Chirurgiche, UOC Malattie Infettive, Fondazione Policlinico Universitario "A.Gemelli" IRCCS, Roma, Italy, [2]Dipartimento di Sicurezza e Bioetica, Sezione Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy, [3]Dipartimento Scienze della Vita e Sanità Pubblica, Igiene e Medicina Preventiva, Università Cattolica del Sacro Cuore, Roma, Italy, [4]UOC Percorsi Clinici e Valutazione degli Outcome, Fondazione Policlinico Universitario "A.Gemelli" IRCCS, Roma, Italy

OC 72 Clinical complexity in people with HIV switching to CAB/RPV versus oral integrase inhibitor–based therapy

G. Loi[1], N. Capra[2], R. Lolatto[2], S. Bagaglio[2], D. Zandonà[2], D. Canetti[2], V. Spagnuolo[1,2], S. Nozza[1,2], A. Castagna[1,2], C. Muccini[2]

[1]Vita-Salute San Raffaele University, Milan, Italy, [2]Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy

OC 73 Intracellular pharmacokinetics and Inhibitory Quotient of Long Acting Cabotegravir and Rilpivirine in the clinical setting

M. Ferrara[1], V. Maccario[1], C. Lipani[1], M. Tettoni[1], L. Trentini[1], G. Orofino[2], E. Martina[3], E. Barnini[3], S. Soloperto[3], A. De Nicolò[3], A. D'Avolio[3], S. Bonora[1]

[1]Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy, [2]Unit of Infectious Diseases, Amedeo di Savoia Hospital, ASL Città di Torino, Italy, [3]Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Torino, Torino, Italy

OC 74 Outcomes of cabotegravir-rilpivirine in key groups of people with HIV (PWH): data from the ICONA cohort

R. Gagliardini[1], A. Tavelli[2,3], A. Giacomelli[4,5], A.R. Raccagni[6,7], V. Mazzotta[1], L. Pipitò[8], L. Brescini[9], S. De Benedittis[2], C. Muccini[6,7], A. Cingolani[10], G. Marchetti[11], A. Antinori[1], A. d'Arminio Monforte[2] on behalf of the Icona Foundation Cohort

[1]National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, [2]ICONA Foundation, Milan, Italy, [3]National PhD Programme in One Health approaches to infectious diseases and life science research, Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy, [4]Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Milan, Italy, [5]Department of Infectious Diseases, ASST Fatebenefratelli Sacco, "L. Sacco" University Hospital, Milan, Italy, [6]Infectious Diseases, Vita-Salute San Raffaele University, Milano, Italy, [7]Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy, [8]Infectious and Tropical Diseases Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G D'Alessandro," University of Palermo, Palermo, Italy, [9]Department of Biomedical Sciences & Public Health, Polytechnic University of Marche, Ancona, Italy, [10]UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Dipartimento di Sicurezza e Bioetica, Università Cattolica del Sacro Cuore, Rome, Italy, [11]Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy

22/05/2026 15.05-16.05 Vaccine response and public health impact in PWH — Sala Mizar

OC 75 From monitoring to impact: increased vaccination coverage in 2025 vs 2024 among people living with HIV in the Lombardy region after implementation of a vaccination coverage monitoring system

D. Cereda[1,2], M. Maffeo[1,2], G. del Castillo[1,2], M.C. Moioli[4], G. Marchetti[5,19], M.V. Cossu[6,2], S. Rusconi[7,19], N. Gemignani[8], F. Crippa[9], E. Focà[10,11], C. Fornabaio[12], B. Menzaghi[13], L. Pagnucco[14,2], B. Mariani[15], N. Squillace[16], D. Canetti[17,18], M. Melazzini[1]

[1]Directorate General for Health - Lombardy Region, Milan, Italy, [2]Regional Center for Infectious Diseases – CEREMI - Lombardy Region, Milan, Italy, [3]Department Biomedical Sciences for Health - University of Milan, Milan, Italy, [4]Department of Infectious Diseases - ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, [5]Infectious diseases unit - ASST Santi Paolo e Carlo, Milan, Italy, [6]ASST Fatebenefratelli Sacco - University Hospital, Milan, Italy, [7]Infectious diseases unit - ASST Ovest Milanese, Legnano, Italy, [8]Infectious diseases unit - ASST Lecco, Lecco, Italy, [9]Infectious diseases unit - ASST Papa Giovanni XXIII, Bergamo, Italy, [10]Infectious diseases unit – ASST Spedali Civili di Brescia, Brescia, Italy, [11]Brescia University, Brescia, Italy, [12]Infectious diseases unit – ASST Cremona, Cremona, Italy, [13]Infectious diseases unit - ASST della Valle Olona, Busto Arsizio, Italy, [14]Division of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, [15]Infectious diseases unit - Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico - University of Milan, Milan, Italy, [16]Infectious Diseases Unit- Fondazione IRCCS, San Gerardo dei Tintori - University of Milano-Bicocca, Monza, Italy, [17]Vita-Salute San Raffaele University, Milan, Italy, [18]IRCCS San Raffaele Scientific Institute, Milan, Italy, [19]University of Milan, Milan, Italy

OC 76 Kinetics of humoral and cellular immune responses up to 3 years after MVA-BN vaccination

V. Mazzotta[1], E. Cimini[2], L. Bordi[3], V. Barchi[1], S. Notari[2], A. Bettini[3], G. Micheli[1], E. Tartaglia[2], C. Mija Casiana[3], R. Schiavone[1], D. Farinacci[1], E. Girardi[4], A. Marani[5], F. Maggi[3], A. Antinori[1,5]

[1]Clinical Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, [2]Laboratory of immunology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, [3]Laboratory of virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, [4]Scientific Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, [5]Health Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy

OC 77 **Prevention of RSV in adults as a strategy to reduce antibiotic consumption and antimicrobial resistance in Italy**

S. Occhineri[1], V. Baldo[2], P. Castiglia[3], G. Gabutti[4], A. Lombardi[5], G. Marchetti[6], M. Falcone[1]
[1]Infectious Diseases Unit, Azienda Ospedaliero Universitaria Pisana AOUP Cisanello, University of Pisa, Pisa, Italy, [2]Department of Molecular Medicine, Public Health Section, University of Padova, Padova, Italy, [3]Department of Medicine, Surgery and Pharmacy, University of Sassari, Italian Scientific Society of Hygiene, Preventive Medicine and Public Health (SItI), Sassari, Italy, [4]Italian Scientific Society of Society of Hygiene, Preventive Medicine and Public Health (SItI), Cogorno (Ge), Adult Immunization Board (AIB), Cogorno, Italy, [5]Infectious Diseases Unit, Fondazione IRCSS Ca' Granda Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, [6]Clinic of Infectious and Tropical Diseases, Department of Health Sciences, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy

OC 78 **T-cell mediated immune responses following recombinant HZ/su vaccine in people with HIV with different CD4+ T-cell count**

V. Sala[1], R. Rovito[1], E. Zaninetta[1], C. Acampora[1], L. Benedetti[2], M. Augello[1], M, Iannetta[2,3], C. Tincati[1], G. Marchetti[1]
[1]San Paolo Hospital, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy, [2]Tor Vergata University of Rome, Rome, Italy, [3]Policlinico Tor Vergata, Rome, Italy